vs
Side-by-side financial comparison of PureCycle Technologies, Inc. (PCT) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PureCycle Technologies, Inc. is the larger business by last-quarter revenue ($2.7M vs $1.4M, roughly 2.0× PLUS THERAPEUTICS, INC.). PLUS THERAPEUTICS, INC. runs the higher net margin — -417.9% vs -697.1%, a 279.2% gap on every dollar of revenue. PLUS THERAPEUTICS, INC. produced more free cash flow last quarter ($-6.3M vs $-42.0M).
PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
PCT vs PSTV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.7M | $1.4M |
| Net Profit | $-18.8M | $-5.7M |
| Gross Margin | — | — |
| Operating Margin | -2196.1% | -420.0% |
| Net Margin | -697.1% | -417.9% |
| Revenue YoY | — | -3.2% |
| Net Profit YoY | 71.0% | -46.4% |
| EPS (diluted) | $-0.14 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.7M | $1.4M | ||
| Q3 25 | $2.4M | $1.4M | ||
| Q2 25 | $1.6M | $1.4M | ||
| Q1 25 | $1.6M | $1.1M | ||
| Q4 24 | $0 | $1.4M | ||
| Q3 24 | $0 | $1.5M | ||
| Q2 24 | $0 | $1.3M | ||
| Q1 24 | $0 | $1.7M |
| Q4 25 | $-18.8M | $-5.7M | ||
| Q3 25 | $-28.4M | $-4.4M | ||
| Q2 25 | $-144.2M | $5.2M | ||
| Q1 25 | $8.8M | $-17.4M | ||
| Q4 24 | $-64.7M | $-3.9M | ||
| Q3 24 | $-90.6M | $-2.9M | ||
| Q2 24 | $-48.2M | $-2.9M | ||
| Q1 24 | $-85.6M | $-3.3M |
| Q4 25 | -2196.1% | -420.0% | ||
| Q3 25 | -1602.2% | -320.8% | ||
| Q2 25 | -2763.5% | -110.6% | ||
| Q1 25 | -2387.4% | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | — | -260.9% | ||
| Q2 24 | — | -289.1% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | -697.1% | -417.9% | ||
| Q3 25 | -1167.5% | -316.6% | ||
| Q2 25 | -8741.8% | 370.6% | ||
| Q1 25 | 559.0% | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | — | -197.4% | ||
| Q2 24 | — | -229.9% | ||
| Q1 24 | — | -194.5% |
| Q4 25 | $-0.14 | $0.95 | ||
| Q3 25 | $-0.31 | $-0.04 | ||
| Q2 25 | $-0.81 | $-0.01 | ||
| Q1 25 | $0.05 | $-1.19 | ||
| Q4 24 | $-0.40 | $-0.51 | ||
| Q3 24 | $-0.54 | $-0.37 | ||
| Q2 24 | $-0.29 | $-0.71 | ||
| Q1 24 | $-0.52 | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $156.7M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.9M | $4.0M |
| Total Assets | $922.7M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $156.7M | $8.6M | ||
| Q3 25 | $234.4M | $16.6M | ||
| Q2 25 | $284.1M | $6.9M | ||
| Q1 25 | $22.5M | $9.9M | ||
| Q4 24 | $15.7M | $3.6M | ||
| Q3 24 | $83.7M | $4.8M | ||
| Q2 24 | $10.9M | $8.4M | ||
| Q1 24 | $25.0M | $3.2M |
| Q4 25 | $45.9M | $4.0M | ||
| Q3 25 | $68.2M | $5.1M | ||
| Q2 25 | $98.9M | $3.0M | ||
| Q1 25 | $238.2M | $-23.6M | ||
| Q4 24 | $180.4M | $-8.9M | ||
| Q3 24 | $241.4M | $-5.2M | ||
| Q2 24 | $291.6M | $-7.6M | ||
| Q1 24 | $336.8M | $-4.8M |
| Q4 25 | $922.7M | $16.3M | ||
| Q3 25 | $989.1M | $18.7M | ||
| Q2 25 | $1.0B | $10.3M | ||
| Q1 25 | $787.3M | $12.1M | ||
| Q4 24 | $798.4M | $6.6M | ||
| Q3 24 | $788.8M | $7.0M | ||
| Q2 24 | $719.8M | $11.2M | ||
| Q1 24 | $734.0M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-28.7M | $-6.3M |
| Free Cash FlowOCF − Capex | $-42.0M | $-6.3M |
| FCF MarginFCF / Revenue | -1559.6% | -459.9% |
| Capex IntensityCapex / Revenue | 495.1% | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-183.6M | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-28.7M | $-6.3M | ||
| Q3 25 | $-38.5M | $-2.5M | ||
| Q2 25 | $-36.7M | $-5.8M | ||
| Q1 25 | $-38.9M | $-6.2M | ||
| Q4 24 | $-31.8M | $-1.2M | ||
| Q3 24 | $-33.4M | $-3.7M | ||
| Q2 24 | $-40.4M | $-1.1M | ||
| Q1 24 | $-39.2M | $-4.5M |
| Q4 25 | $-42.0M | $-6.3M | ||
| Q3 25 | $-42.4M | $-2.6M | ||
| Q2 25 | $-45.3M | $-5.8M | ||
| Q1 25 | $-53.9M | $-6.2M | ||
| Q4 24 | $-53.4M | $-1.2M | ||
| Q3 24 | $-42.6M | $-3.7M | ||
| Q2 24 | $-50.8M | $-1.2M | ||
| Q1 24 | $-53.5M | $-4.6M |
| Q4 25 | -1559.6% | -459.9% | ||
| Q3 25 | -1743.1% | -184.3% | ||
| Q2 25 | -2747.1% | -417.6% | ||
| Q1 25 | -3409.6% | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -271.5% |
| Q4 25 | 495.1% | 2.2% | ||
| Q3 25 | 160.3% | 1.9% | ||
| Q2 25 | 521.5% | 0.5% | ||
| Q1 25 | 949.6% | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | -4.40× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
